Triveram
Commercial- Indications
- Cardiovascular disease
Company intelligence / Profile preview
Biogaran
Colombes, Francebiogaran.com ↗
- Ownership
- Private
- Employees
- ~750
- Development stage
- Commercial
01
Overview
Biogaran leads the French generic drug market with over 300 million boxes sold annually. It has expanded into biosimilars since launching its first in February 2015. The company’s portfolio covers both retail and hospital markets with approved generics and biosimilars targeting major chronic diseases such as hypertension, diabetes, and cardiovascular conditions. Clinical results are consistent with regulatory standards for bioequivalence.
- Therapeutic areas
- Metabolic DisordersPulmonologyCardiovascularEndocrinology
- Modalities
- Small moleculesBiosimilars (biological drugs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ROVI – partnership to market enoxaparin biosimilar in France
Beyond the preview
Go deeper on Biogaran.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biogaran.